Smartest Doc
A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS-A pilot study
Pediatric Rheumatology, 08/20/2012
Rana A et al. – The authors conclude that 2–D maps of patients with active paediatric systemic lupus erythematosus (pSLE) and controls differ significantly. In this pilot study, using proteomic approach the authors have identified differential expressed proteins e.g., retinol binding protein, leiomodin 2, transthyretin, Component C3c Chain B and apolipoprotein A1. However, in future, further studies need to confirm the physiological and pathological role of these proteins in similar cohorts of pSLE.
Methods- 2D–PAGE was performed using pooled sera of active pSLE and age matched healthy controls.
- Gels were silver–stained and differentially expressed protein spots were detected by automated image master platinum 2D software.
- 79 +/– 17 protein spots were detected for control gels and 78 +/– 17 protein spots for patient gels.
- Of these eleven protein spots were selected randomly and characterized by MALDI–TOF MS (five protein spots) and LC MS (six protein spots) techniques.
- Out of the 11 protein spots, 5 protein spots were significantly upregulated viz., leiomodin 2 (LMOD2); epidermal cytokeratin 2; immunoglobulin kappa light chain variable region; keratin 1 and transthyretin (TTR).
- Three protein spots were significantly down regulated e.g., apolipoprotein A1 (APOA1); chain B human complement component C3c; campath antibody antigen complex.
- Two protein spots (complement component C3; retinol binding protein (RBP) were found to be expressed only in disease and one protein spot cyclohydrolase 2 was only expressed in controls.